14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results